Global Oncology Biosimilars Market Size study, By Indication (Atopic Dermatitis, Postoperative Immunosuppression, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, Others), By Drug Class (Cyclosporine, Tacrolimus, Pimecrolimus, Others), By Route of Administration (Oral, Topical, Parenteral), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Regional Forecasts 2022-2028
Global Oncology Biosimilars Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Oncology Biosimilars can be defined as a version of a known and proven biologic drug. These drugs are made from living things such as cells, tissues, or proteins. Biosimilars are more affordable alternatives to similar other drugs. Also, biosimilar offers similar safety and toxicity profile. Growing prevalence of cancer worldwide and increasing demand for biosimilar drugs due to affordability as well as recent partnerships and product launches from leading players are key drivers for growth of Oncology Biosimilars Market. For instance, according to World Cancer Research Fund – in 2020, around 18.1 million cancer cases were reported globally. Around 9.3 million cases were in men and 8.8 million in women. Further, Breast and lung cancers were most prevalent type of cancers worldwide, contributing 12.5% and 12.2% of all cancer cases reported in 2020. Moreover, in March 2019, the United States (U.S.) Food and Drug Administration (FDA) has approved new biosimilar from Pfizer Inc. named TRAZIMERA (trastuzumab-qyyp). This new drug is a biosimilar to Herceptin (trastuzumab). This new drug is intended for the treatment of breast cancer and Esophageal cancer. Further, in March 2022, Cipla Medpro, a wholly owned subsidiary of Cipla Limited, India entered in a partnership agreement with Madrid, Spain based mAbxience. Under this partnership both the companies would work towards bringing oncology and respiratory-related biosimilars to South Africa region. Also, growing spending on pharmaceuticals research and rising healthcare infrastructure in emerging economies are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high cost associated with the drug development & distribution and complex process of drug development and approvals impede the growth of the market over the forecast period of 2022-2028.
The key regions considered for the global Oncology Biosimilars Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of cancer as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing number of pharmaceutical contract manufacturers and rising healthcare spending in the region, would create lucrative growth prospects for the Oncology Biosimilars Market across the Asia Pacific region.
Major market players included in this report are:
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Zydus Cadila (India)
Lupin (India)
Amneal Pharmaceuticals LLC. (U.S.)
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Oncology Biosimilars Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
The key regions considered for the global Oncology Biosimilars Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to rising R&D activities and increasing prevalence of cancer as well as presence of leading market players. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as growing number of pharmaceutical contract manufacturers and rising healthcare spending in the region, would create lucrative growth prospects for the Oncology Biosimilars Market across the Asia Pacific region.
Major market players included in this report are:
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
F. Hoffmann-La Roche Ltd. (Switzerland)
Zydus Cadila (India)
Lupin (India)
Amneal Pharmaceuticals LLC. (U.S.)
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Oncology Biosimilars Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
1.2.1. Global Oncology Biosimilars Market, by Region, 2020-2028 (USD Million)
1.2.2. Global Oncology Biosimilars Market, by Indication, 2020-2028 (USD Million)
1.2.3. Global Oncology Biosimilars Market, by Drug Class, 2020-2028 (USD Million)
1.2.4. Global Oncology Biosimilars Market, by Route of Administration, 2020-2028 (USD Million)
1.2.5. Global Oncology Biosimilars Market, by End-Users, 2020-2028 (USD Million)
1.2.6. Global Oncology Biosimilars Market, by Distribution Channel, 2020-2028 (USD Million)
1.2.7.
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET DYNAMICS
3.1. Oncology Biosimilars Market Impact Analysis (2020-2028)
3.1.1. Market Drivers
3.1.1.1. Growing prevalence of cancer worldwide.
3.1.1.2. increasing demand for biosimilar drugs due to affordability.
3.1.1.3. Recent partnerships and product launches from leading players.
3.1.2. Market Challenges
3.1.2.1. high cost associated with the drug development & distribution.
3.1.2.2. Complex process of drug development and approvals.
3.1.3. Market Opportunities
3.1.3.1. Growing spending on pharmaceuticals research.
3.1.3.2. Rising healthcare infrastructure in emerging economies.
CHAPTER 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY INDICATION
6.1. Market Snapshot
6.2. Global Oncology Biosimilars Market by Indication, Performance - Potential Analysis
6.3. Global Oncology Biosimilars Market Estimates & Forecasts by Indication 2018-2028 (USD Million)
6.4. Oncology Biosimilars Market, Sub Segment Analysis
6.4.1. Breast Cancer
6.4.2. Lung Cancer
6.4.3. Colorectal Cancer
6.4.4. Cervical Cancer
6.4.5. Blood Cancer
6.4.6. Others
CHAPTER 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS
7.1. Market Snapshot
7.2. Global Oncology Biosimilars Market by Drug Class, Performance - Potential Analysis
7.3. Global Oncology Biosimilars Market Estimates & Forecasts by Drug Class 2018-2028 (USD Million)
7.4. Oncology Biosimilars Market, Sub Segment Analysis
7.4.1. Monoclonal Antibodies
7.4.2. Granulocyte Colony-Stimulating Factor
7.4.3. Others
CHAPTER 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION
8.1. Market Snapshot
8.2. Global Oncology Biosimilars Market by Route of Administration, Performance - Potential Analysis
8.3. Global Oncology Biosimilars Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
8.4. Oncology Biosimilars Market, Sub Segment Analysis
8.4.1. Intravenous
8.4.2. Subcutaneous
8.4.3. Others
CHAPTER 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY END-USERS
9.1. Market Snapshot
9.2. Global Oncology Biosimilars Market by End-Users, Performance - Potential Analysis
9.3. Global Oncology Biosimilars Market Estimates & Forecasts by End-Users 2018-2028 (USD Million)
9.4. Oncology Biosimilars Market, Sub Segment Analysis
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Homecare
9.4.4. Others
CHAPTER 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL
10.1. Market Snapshot
10.2. Global Oncology Biosimilars Market by Distribution Channel, Performance - Potential Analysis
10.3. Global Oncology Biosimilars Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
10.4. Oncology Biosimilars Market, Sub Segment Analysis
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.4.4. Others
CHAPTER 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET, REGIONAL ANALYSIS
11.1. Oncology Biosimilars Market, Regional Market Snapshot
11.2. North America Oncology Biosimilars Market
11.2.1. U.S. Oncology Biosimilars Market
11.2.1.1. Indication estimates & forecasts, 2018-2028
11.2.1.2. Drug Class estimates & forecasts, 2018-2028
11.2.1.3. Route of Administration estimates & forecasts, 2018-2028
11.2.1.4. End-Users estimates & forecasts, 2018-2028
11.2.1.5. Distribution Channel estimates & forecasts, 2018-2028
11.2.2. Canada Oncology Biosimilars Market
11.3. Europe Oncology Biosimilars Market Snapshot
11.3.1. U.K. Oncology Biosimilars Market
11.3.2. Germany Oncology Biosimilars Market
11.3.3. France Oncology Biosimilars Market
11.3.4. Spain Oncology Biosimilars Market
11.3.5. Italy Oncology Biosimilars Market
11.3.6. Rest of Europe Oncology Biosimilars Market
11.4. Asia-Pacific Oncology Biosimilars Market Snapshot
11.4.1. China Oncology Biosimilars Market
11.4.2. India Oncology Biosimilars Market
11.4.3. Japan Oncology Biosimilars Market
11.4.4. Australia Oncology Biosimilars Market
11.4.5. South Korea Oncology Biosimilars Market
11.4.6. Rest of Asia Pacific Oncology Biosimilars Market
11.5. Latin America Oncology Biosimilars Market Snapshot
11.5.1. Brazil Oncology Biosimilars Market
11.5.2. Mexico Oncology Biosimilars Market
11.6. Rest of The World Oncology Biosimilars Market
CHAPTER 12. COMPETITIVE INTELLIGENCE
12.1. Top Market Strategies
12.2. Company Profiles
12.2.1. Pfizer Inc. (US)
12.2.1.1. Key Information
12.2.1.2. Overview
12.2.1.3. Financial (Subject to Data Availability)
12.2.1.4. Product Summary
12.2.1.5. Recent Developments
12.2.2. GlaxoSmithKline plc (U.K.)
12.2.3. Novartis AG (Switzerland)
12.2.4. Mylan N.V. (U.S.)
12.2.5. Teva Pharmaceutical Industries Ltd. (Israel)
12.2.6. Sanofi (France)
12.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
12.2.8. Zydus Cadila (India)
12.2.9. Lupin (India)
12.2.10. Amneal Pharmaceuticals LLC. (U.S.)
CHAPTER 13. RESEARCH PROCESS
13.1. Research Process
13.1.1. Data Mining
13.1.2. Analysis
13.1.3. Market Estimation
13.1.4. Validation
13.1.5. Publishing
13.2. Research Attributes
13.3. Research Assumption
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
1.2.1. Global Oncology Biosimilars Market, by Region, 2020-2028 (USD Million)
1.2.2. Global Oncology Biosimilars Market, by Indication, 2020-2028 (USD Million)
1.2.3. Global Oncology Biosimilars Market, by Drug Class, 2020-2028 (USD Million)
1.2.4. Global Oncology Biosimilars Market, by Route of Administration, 2020-2028 (USD Million)
1.2.5. Global Oncology Biosimilars Market, by End-Users, 2020-2028 (USD Million)
1.2.6. Global Oncology Biosimilars Market, by Distribution Channel, 2020-2028 (USD Million)
1.2.7.
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET DYNAMICS
3.1. Oncology Biosimilars Market Impact Analysis (2020-2028)
3.1.1. Market Drivers
3.1.1.1. Growing prevalence of cancer worldwide.
3.1.1.2. increasing demand for biosimilar drugs due to affordability.
3.1.1.3. Recent partnerships and product launches from leading players.
3.1.2. Market Challenges
3.1.2.1. high cost associated with the drug development & distribution.
3.1.2.2. Complex process of drug development and approvals.
3.1.3. Market Opportunities
3.1.3.1. Growing spending on pharmaceuticals research.
3.1.3.2. Rising healthcare infrastructure in emerging economies.
CHAPTER 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
CHAPTER 5. RISK ASSESSMENT: COVID-19 IMPACT
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 Market scenario
CHAPTER 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY INDICATION
6.1. Market Snapshot
6.2. Global Oncology Biosimilars Market by Indication, Performance - Potential Analysis
6.3. Global Oncology Biosimilars Market Estimates & Forecasts by Indication 2018-2028 (USD Million)
6.4. Oncology Biosimilars Market, Sub Segment Analysis
6.4.1. Breast Cancer
6.4.2. Lung Cancer
6.4.3. Colorectal Cancer
6.4.4. Cervical Cancer
6.4.5. Blood Cancer
6.4.6. Others
CHAPTER 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DRUG CLASS
7.1. Market Snapshot
7.2. Global Oncology Biosimilars Market by Drug Class, Performance - Potential Analysis
7.3. Global Oncology Biosimilars Market Estimates & Forecasts by Drug Class 2018-2028 (USD Million)
7.4. Oncology Biosimilars Market, Sub Segment Analysis
7.4.1. Monoclonal Antibodies
7.4.2. Granulocyte Colony-Stimulating Factor
7.4.3. Others
CHAPTER 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY ROUTE OF ADMINISTRATION
8.1. Market Snapshot
8.2. Global Oncology Biosimilars Market by Route of Administration, Performance - Potential Analysis
8.3. Global Oncology Biosimilars Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
8.4. Oncology Biosimilars Market, Sub Segment Analysis
8.4.1. Intravenous
8.4.2. Subcutaneous
8.4.3. Others
CHAPTER 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY END-USERS
9.1. Market Snapshot
9.2. Global Oncology Biosimilars Market by End-Users, Performance - Potential Analysis
9.3. Global Oncology Biosimilars Market Estimates & Forecasts by End-Users 2018-2028 (USD Million)
9.4. Oncology Biosimilars Market, Sub Segment Analysis
9.4.1. Hospitals
9.4.2. Specialty Clinics
9.4.3. Homecare
9.4.4. Others
CHAPTER 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET, BY DISTRIBUTION CHANNEL
10.1. Market Snapshot
10.2. Global Oncology Biosimilars Market by Distribution Channel, Performance - Potential Analysis
10.3. Global Oncology Biosimilars Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
10.4. Oncology Biosimilars Market, Sub Segment Analysis
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.4.4. Others
CHAPTER 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET, REGIONAL ANALYSIS
11.1. Oncology Biosimilars Market, Regional Market Snapshot
11.2. North America Oncology Biosimilars Market
11.2.1. U.S. Oncology Biosimilars Market
11.2.1.1. Indication estimates & forecasts, 2018-2028
11.2.1.2. Drug Class estimates & forecasts, 2018-2028
11.2.1.3. Route of Administration estimates & forecasts, 2018-2028
11.2.1.4. End-Users estimates & forecasts, 2018-2028
11.2.1.5. Distribution Channel estimates & forecasts, 2018-2028
11.2.2. Canada Oncology Biosimilars Market
11.3. Europe Oncology Biosimilars Market Snapshot
11.3.1. U.K. Oncology Biosimilars Market
11.3.2. Germany Oncology Biosimilars Market
11.3.3. France Oncology Biosimilars Market
11.3.4. Spain Oncology Biosimilars Market
11.3.5. Italy Oncology Biosimilars Market
11.3.6. Rest of Europe Oncology Biosimilars Market
11.4. Asia-Pacific Oncology Biosimilars Market Snapshot
11.4.1. China Oncology Biosimilars Market
11.4.2. India Oncology Biosimilars Market
11.4.3. Japan Oncology Biosimilars Market
11.4.4. Australia Oncology Biosimilars Market
11.4.5. South Korea Oncology Biosimilars Market
11.4.6. Rest of Asia Pacific Oncology Biosimilars Market
11.5. Latin America Oncology Biosimilars Market Snapshot
11.5.1. Brazil Oncology Biosimilars Market
11.5.2. Mexico Oncology Biosimilars Market
11.6. Rest of The World Oncology Biosimilars Market
CHAPTER 12. COMPETITIVE INTELLIGENCE
12.1. Top Market Strategies
12.2. Company Profiles
12.2.1. Pfizer Inc. (US)
12.2.1.1. Key Information
12.2.1.2. Overview
12.2.1.3. Financial (Subject to Data Availability)
12.2.1.4. Product Summary
12.2.1.5. Recent Developments
12.2.2. GlaxoSmithKline plc (U.K.)
12.2.3. Novartis AG (Switzerland)
12.2.4. Mylan N.V. (U.S.)
12.2.5. Teva Pharmaceutical Industries Ltd. (Israel)
12.2.6. Sanofi (France)
12.2.7. F. Hoffmann-La Roche Ltd. (Switzerland)
12.2.8. Zydus Cadila (India)
12.2.9. Lupin (India)
12.2.10. Amneal Pharmaceuticals LLC. (U.S.)
CHAPTER 13. RESEARCH PROCESS
13.1. Research Process
13.1.1. Data Mining
13.1.2. Analysis
13.1.3. Market Estimation
13.1.4. Validation
13.1.5. Publishing
13.2. Research Attributes
13.3. Research Assumption
LIST OF TABLES
List of Tables
TABLE 1. Global Oncology Biosimilars Market, report scope
TABLE 2. Global Oncology Biosimilars Market estimates & forecasts by Region 2018-2028 (USD Million)
TABLE 3. Global Oncology Biosimilars Market estimates & forecasts by Indication 2018-2028 (USD Million)
TABLE 4. Global Oncology Biosimilars Market estimates & forecasts by Drug Class 2018-2028 (USD Million)
TABLE 5. Global Oncology Biosimilars Market estimates & forecasts by Route of Administration 2018-2028 (USD Million)
TABLE 6. Global Oncology Biosimilars Market estimates & forecasts by End-Users 2018-2028 (USD Million)
TABLE 7. Global Oncology Biosimilars Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
TABLE 8. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 9. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 10. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 11. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 12. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 13. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 14. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 15. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 16. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 17. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 18. U.S. Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 19. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 20. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 21. Canada Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 22. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 23. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 24. UK Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 25. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 26. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 27. Germany Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 28. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 29. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 30. RoE Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 31. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 32. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 33. China Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 34. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 35. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 36. India Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 37. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 38. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 39. Japan Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 40. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 41. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 42. RoAPAC Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 43. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 44. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 45. Brazil Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 46. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 47. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 48. Mexico Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 49. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 50. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 51. RoLA Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 52. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 53. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 54. Row Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 55. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 56. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 57. List of secondary sources, used in the study of global Oncology Biosimilars Market
TABLE 58. List of primary sources, used in the study of global Oncology Biosimilars Market
TABLE 59. Years considered for the study
TABLE 60. Exchange rates considered
List of Tables
TABLE 1. Global Oncology Biosimilars Market, report scope
TABLE 2. Global Oncology Biosimilars Market estimates & forecasts by Region 2018-2028 (USD Million)
TABLE 3. Global Oncology Biosimilars Market estimates & forecasts by Indication 2018-2028 (USD Million)
TABLE 4. Global Oncology Biosimilars Market estimates & forecasts by Drug Class 2018-2028 (USD Million)
TABLE 5. Global Oncology Biosimilars Market estimates & forecasts by Route of Administration 2018-2028 (USD Million)
TABLE 6. Global Oncology Biosimilars Market estimates & forecasts by End-Users 2018-2028 (USD Million)
TABLE 7. Global Oncology Biosimilars Market estimates & forecasts by Distribution Channel 2018-2028 (USD Million)
TABLE 8. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 9. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 10. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 11. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 12. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 13. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 14. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 15. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 16. Global Oncology Biosimilars Market by segment, estimates & forecasts, 2018-2028 (USD Million)
TABLE 17. Global Oncology Biosimilars Market by region, estimates & forecasts, 2018-2028 (USD Million)
TABLE 18. U.S. Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 19. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 20. U.S. Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 21. Canada Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 22. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 23. Canada Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 24. UK Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 25. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 26. UK Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 27. Germany Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 28. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 29. Germany Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 30. RoE Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 31. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 32. RoE Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 33. China Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 34. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 35. China Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 36. India Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 37. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 38. India Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 39. Japan Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 40. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 41. Japan Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 42. RoAPAC Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 43. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 44. RoAPAC Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 45. Brazil Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 46. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 47. Brazil Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 48. Mexico Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 49. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 50. Mexico Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 51. RoLA Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 52. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 53. RoLA Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 54. Row Oncology Biosimilars Market estimates & forecasts, 2018-2028 (USD Million)
TABLE 55. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 56. Row Oncology Biosimilars Market estimates & forecasts by segment 2018-2028 (USD Million)
TABLE 57. List of secondary sources, used in the study of global Oncology Biosimilars Market
TABLE 58. List of primary sources, used in the study of global Oncology Biosimilars Market
TABLE 59. Years considered for the study
TABLE 60. Exchange rates considered
LIST OF FIGURES
FIG 1. Global Oncology Biosimilars Market, research methodology
FIG 2. Global Oncology Biosimilars Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Oncology Biosimilars Market, key trends 2021
FIG 5. Global Oncology Biosimilars Market, growth prospects 2022-2028
FIG 6. Global Oncology Biosimilars Market, porters 5 force model
FIG 7. Global Oncology Biosimilars Market, pest analysis
FIG 8. Global Oncology Biosimilars Market, value chain analysis
FIG 9. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 10. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 11. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 12. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 13. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 14. Global Oncology Biosimilars Market, regional snapshot 2018 & 2028
FIG 15. North America Oncology Biosimilars Market 2018 & 2028 (USD Million)
FIG 16. Europe Oncology Biosimilars Market 2018 & 2028 (USD Million)
FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
FIG 18. Latin America Oncology Biosimilars Market 2018 & 2028 (USD Million)
FIG 19. Global Oncology Biosimilars Market, company Market share analysis (2021)
FIG 1. Global Oncology Biosimilars Market, research methodology
FIG 2. Global Oncology Biosimilars Market, Market estimation techniques
FIG 3. Global Market size estimates & forecast methods
FIG 4. Global Oncology Biosimilars Market, key trends 2021
FIG 5. Global Oncology Biosimilars Market, growth prospects 2022-2028
FIG 6. Global Oncology Biosimilars Market, porters 5 force model
FIG 7. Global Oncology Biosimilars Market, pest analysis
FIG 8. Global Oncology Biosimilars Market, value chain analysis
FIG 9. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 10. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 11. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 12. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 13. Global Oncology Biosimilars Market by segment, 2018 & 2028 (USD Million)
FIG 14. Global Oncology Biosimilars Market, regional snapshot 2018 & 2028
FIG 15. North America Oncology Biosimilars Market 2018 & 2028 (USD Million)
FIG 16. Europe Oncology Biosimilars Market 2018 & 2028 (USD Million)
FIG 17. Asia pacific Market 2018 & 2028 (USD Million)
FIG 18. Latin America Oncology Biosimilars Market 2018 & 2028 (USD Million)
FIG 19. Global Oncology Biosimilars Market, company Market share analysis (2021)
